Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evaluation of the Clinical Efficacy of Y-STRUT® Medical Device Implanted for Contralateral Percutaneous Internal Fixation of Proximal Femur, in Patient With a Low Energy Per Trochanteric Fracture on the First Side

27. april 2020 opdateret af: Hyprevention

National, Multicentre, Prospective, Observational Study, to Evaluate the Clinical Efficacy of Y-STRUT® Medical Device Implanted for Contralateral Percutaneous Internal Fixation of Proximal Femur, in Patient With a Low Energy Per Trochanteric Fracture on the First Side

HIP50 is a national, multicentre, prospective, observational study, in patients presenting a first low energy per trochanteric hip fracture on one side and treated with Y-STRUT® device implanted on the contralateral proximal femur as percutaneous internal fixation to prevent contralateral hip fracture in case of osteoporosis.

The primary objective of this study is to evaluate the clinical efficacy of the studied medical device by measuring the frequency of patient with a fracture at the implantation site within 1 year after implantation.

A total of 50 patients from France will be enrolled (until December 2020) and followed up to 24 months.

Studieoversigt

Status

Afsluttet

Betingelser

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

10

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Ambérieu-en-Bugey, Frankrig, 01500
        • Hôpital Privé d'Ambérieu
      • Clamart, Frankrig, 92140
        • Hôpital Antoine Béclère
      • La Tronche, Frankrig, 38700
        • Centre Hospitalier Universitaire Grenoble Alpes
      • Orléans, Frankrig, 45100
        • Centre Hospitalier Régional Orléans
      • Tours, Frankrig, 37000
        • Nouvelle Clinique de Tours Plus St Gatien

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

60 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patients presenting a first low energy per trochanteric hip fracture on one side and treated with Y-STRUT® device implanted on the contralateral proximal femur as percutaneous internal fixation.

Beskrivelse

Inclusion Criteria:

  • Patient of 60 years and older, according to CE indication;
  • Patient with information form signed to participate in the study;
  • Patients presenting a first low energy hip fracture on one side and having a Y-STRUT® device implanted on the contralateral hip between 0 and 120 days after the treatment of the fracture of the first hip;

Exclusion Criteria:

  • Patient who refuse to participate to this study;
  • Patient implanted with Y-STRUT® for another indication;
  • Patient already enrolled in a clinical study, excluding his participation to HIP50.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Frequency of post-operative fracture [Clinical efficacy of the device]
Tidsramme: At 12 months
Frequency of Y-STRUT® implanted patients with a fracture at the implantation site
At 12 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Frequency of post-operative fracture [Clinical efficacy of the device]
Tidsramme: At 3 and 24 months
Frequency of Y-STRUT® implanted patients with a fracture at the implantation site
At 3 and 24 months
Recording of concomitants treatments [safety and feasibility of the device]
Tidsramme: At 3, 12 and 24 months
Recording of all concomitants treatments: analgesic for pain, anti-osteoporotic treatment and other treatments.
At 3, 12 and 24 months
Pain [safety and feasibility of the device]
Tidsramme: At 3, 12 and 24 months
Self-evaluation of hip pain using VAS (Visual Analogue Scale), going from 0 (no pain) to 10 (maximum).
At 3, 12 and 24 months
Walking conditions [safety and feasibility of the device]
Tidsramme: At 3, 12 and 24 months
Assessment of resumption of weight-bearing (yes/no, aid)
At 3, 12 and 24 months
Recording of adverse events and device effects [safety and feasibility of the device]
Tidsramme: At 3, 12 and 24 months
Recording of the medical device vigilance: all serious adverse events, all adverse events linked to the device or the operative technique, and any other important event reported.
At 3, 12 and 24 months
Surgical procedure duration [learning curve of the procedure]
Tidsramme: At the end of the inclusion period (24 months from the first included patient)
Measuring mean/median intervention duration of each procedure. Then, all the durations of successive procedures will be compared among all the investigators.
At the end of the inclusion period (24 months from the first included patient)
Hospitalisation duration [learning curve of the procedure]
Tidsramme: At the end of the inclusion period (24 months from the first included patient)]
Measuring mean/median hospitalisation duration. Then, all the durations of successive hospitalisations will be compared among all the investigators.
At the end of the inclusion period (24 months from the first included patient)]
Rate of complications [learning curve of the procedure]
Tidsramme: At the end of the inclusion period (24 months from the first included patient)
Assessing types and frequencies of procedures complications (per-op and post-op). Then, all the rate of complications will be compared among all the investigators.
At the end of the inclusion period (24 months from the first included patient)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

6. december 2017

Primær færdiggørelse (Faktiske)

24. marts 2020

Studieafslutning (Faktiske)

24. marts 2020

Datoer for studieregistrering

Først indsendt

21. august 2018

Først indsendt, der opfyldte QC-kriterier

23. august 2018

Først opslået (Faktiske)

27. august 2018

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. april 2020

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

27. april 2020

Sidst verificeret

1. april 2020

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Y-STRUT® (Hyprevention, Pessac, Frankrig)

3
Abonner